Brought to you by 
Eisai markets Pfizer's Cerebyx for seizures
Aug 2002
Executive Summary
Eisai will exclusively market Pfizer's Cerebyx (fosphenytoin sodium injection) in the US.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com